Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations

  title={Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations},
  author={R. Brett McQueen and Danielle N. Sheehan and Melanie D. Whittington and Job Fm Van Boven and Jonathan D. Campbell},
BackgroundRecently developed asthma biological therapies have been shown to provide relief for severe asthma patients not controlled by inhaled treatment. Given the relatively high costs of biological therapies, cost-effectiveness analyses (CEAs) may be required as a prerequisite for coverage and reimbursement.ObjectiveWe aimed to systematically review published literature on the economic impact of biological asthma therapies and to identify key drivers that impact cost-effectiveness in order… 

A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions.

Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States

Using broader evidence on treatment discontinuation, caregiver burden, and oral corticosteroid reduction from real-world studies may better reflect the effects and value of omalizumab for all healthcare stakeholders.

Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan.

  • Y. TohdaH. Matsumoto I. Arakawa
  • Medicine, Political Science
    The Journal of asthma : official journal of the Association for the Care of Asthma
  • 2021
Treatment with dupilumab leads to fewer severe exacerbations and increased life-years (LYs) and quality-adjusted LYs (QALYs) than benralizumab and mepolizuab, and at a willingness-to-pay (WTP) threshold of ¥5,000,000 per QALY gained, dupILumab was the dominant strategy.

Real-life cost-effectiveness of benralizumab in patients with severe asthma

All the pharmacoeconomic parameters analysed show that treatment with benralizumab is a cost-effective option as an add-on therapy in patients with refractory eosinophilic asthma.

Cost-effectiveness analysis of anti–IL-5 therapies of severe eosinophilic asthma in Spain

MEP is a cost-effective treatment in comparison with BEN and RES added to SoC for patients with SEA in the Spanish setting, and the findings were robust to variation as estimated using sensitivity analysis.

Economic considerations on the usage of biologics in the allergy clinic

Despite the good quality of most cost‐utility analyses conducted for the use of biologics in asthma and other atopic diseases, their conclusions regarding cost‐effectiveness are extremely variable and development of reliable and validated instruments to measure disutility in atopic disorders are identified as a priority for future research.

Cost-Effectiveness of Pulmonary Rehabilitation in Patients With Bronchial Asthma: An Analysis of the EPRA Randomized Controlled Trial.

Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study

Omalizumab was shown to be an effective add-on therapy for patients with persistent severe asthma and allowed reducing key drivers of asthma-related costs.

Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma.

The cost comparison between mepolizumab and omalizumAB in immunoglobulin E mediated eosinophilic asthma patients suggests a use of the lower cost drug, promoting price competition.

Cost effectiveness of benralizumab for severe, uncontrolled oral corticosteroid–dependent asthma in Sweden

It is demonstrated that benralizumab has a high probability of being cost-effective compared with SOC plus OCS for a subgroup of patients with severe, eosinophilic asthma receiving regular OCS treatment and may support clinicians, payers and patients in making treatment decisions.



Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis.

  • R. FariaC. McKennaS. Palmer
  • Medicine, Political Science
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2014

Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain

The results of this study confirm the effectiveness of the addition of omalizumab to standard therapy in patients with uncontrolled severe persistent asthma.

Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands

Non-clinical trial experience with omalizumab supported the finding of fewer exacerbations in the allergic asthma population while treated with o malzumab, and therapy was found to continue to have an attractive cost-effectiveness ratio.

Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US

Add-on therapy with tiotropium was a cost-effective alternative to omalizumab and standard therapy for uncontrolled allergic asthma at willingness-to-pay of $50,000/QALY.

Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective

Adding omalizumab to the treatment of patients with uncontrolled severe persistent asthma reduces the number of exacerbations with ER visits and increases health-related quality of life after 10 months of treatment and produces ICERs favorable to omalzumab and acceptable from the health system perspective.

Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.

Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma.

Real-world health care utilization and effectiveness of omalizumab for the treatment of severe asthma.

  • Mina TadrousW. Khuu T. Gomes
  • Medicine, Political Science
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2018

Asthma outcomes: healthcare utilization and costs.